EGFR and non-small cell lung carcinoma: In a recent cohort study including 862 patients prescribed with osimertinib for EGFR-mutant NSCLC of any stage,28 for patients with cardiotoxic effects, the time from LVEF decrease to death was very short, with a median of only 3.2 (IQR, 1.7-18.4) months.